Merck, a leading science and technology company, today announced the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the init...
Partnership will leverage Aspect’s proprietary bioprinting technology and Novo Nordisk’s expertise and technology in stem cell differentiation ...
"We remain confident in mirikizumab's pivotal Phase 3 clinical data and its potential to help people with ulcerative colitis," said Patrik Jonsson, Lilly e...
OM1, a leading real-world data, outcomes and technology company with a focus on chronic conditions, today launched PhenOM™, its artificial intelligen...
During aging, the central nervous system (“CNS”) becomes more inflammatory, leading to activation of microglia (“CNS immune cells&rdquo...
The published data showcase how Evaxion's proprietary AI-platform, RAVEN (Rapidly Adaptive Viral Response), identifies broad and robust T-cell epitopes fro...
Agilent Technologies Inc. (NYSE: A) today announced a strategic partnership with PathAI, a leading provider of AI-powered research tools and serv...
Cold Spring Harbor Laboratory Professor Adrian Krainer is best known for his groundbreaking research on antisense oligonucleotides (ASOs)—m...
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medic...
"Completion of enrollment in the first cohort of the Phase 1b MAD study is an important milestone in the development of this novel treatment for ADPKD," sa...
To participate, call 833-470-1428 within the U.S. or +1 929-526-1599 outside the U.S., access code: 522530. A live webcast of the conference call will also...
Hypoimmune human islet cells normalized glucose in diabetic humanized immunocompetent mouse model and avoided allogeneic and autoimmune rejection by the im...
This collaboration extends preferred pricing on RxToolKit's software solutions in addition to other exclusive benefits already available to NeuroNet Pro me...
The Barbara Ann Karmanos Cancer Institute, a leading breast cancer prevention and care provider, has adopted Volpara® Risk Pathways™, a market-le...
© 2025 Biopharma Boardroom. All Rights Reserved.
